Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore

Breast Cancer Research and Treatment

Volumn 130, Issue 3, 2011, Pages 1011-1019

  Koh, Woon Puay ^a   Van Den Berg, David ^b   Jin, Aizhen ^c   Wang, Renwei ^d   Yuan, Jian Min ^d,e   Yu, Mimi C ^d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Health Promotion Board Singapore   (Singapore)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; Chinese; MDM2; p53; Soy isoflavones

Indexed keywords

ARGININE; GUANINE; ISOFLAVONE DERIVATIVE; PROLINE; PROTEIN MDM2; THYMINE;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOOD INTAKE; GENE ACTIVITY; GENE DOSAGE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE MDM2; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; ISOFLAVONES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SINGAPORE; SOY FOODS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82255175076     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1680-2     Document Type: Article

References (51)

1. S Jin AJ Levine 2001 The p53 functional circuit J Cell Sci 114 4139 4140 11739646 1:CAS:528:DC%2BD3MXptlKrt7o%3D (Pubitemid 33138651)
2. S Lain D Lane 2003 Improving cancer therapy by non-genotoxic activation of p53 Eur J Cancer 39 1053 1060 12736103 10.1016/S0959-8049(03)00063-7 1:CAS:528:DC%2BD3sXjsVarurs%3D (Pubitemid 36555861)
3. S Ara PS Lee MF Hansen H Saya 1990 Codon 72 polymorphism of the TP53 gene Nucleic Acids Res 18 4961 1975675 10.1093/nar/18.16.4961 1:CAS:528: DyaK3cXls1Kksr0%3D (Pubitemid 20280142)
4. M Thomas A Kalita S Labrecque D Pim L Banks G Matlashewski 1999 Two polymorphic variants of wild-type p53 differ biochemically and biologically Mol Cell Biol 19 1092 1100 9891044 1:CAS:528:DyaK1MXhtVKhsL0%3D (Pubitemid 29046852)
5. D Michael M Oren 2002 The p53 and Mdm2 families in cancer Curr Opin Genet Dev 12 53 59 11790555 10.1016/S0959-437X(01)00264-7 1:CAS:528: DC%2BD38XktFGlsg%3D%3D (Pubitemid 34094990)
6. GL Bond W Hu EE Bond, et al. 2004 A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 591 602 15550242 10.1016/j.cell.2004.11.022 1:CAS:528:DC%2BD2cXhtVGls7bF (Pubitemid 39535748)
7. SN Jones AR Hancock H Vogel LA Donehower A Bradley 1998 Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis Proc Natl Acad Sci USA 95 15608 15612 9861017 10.1073/pnas.95.26.15608 1:CAS:528:DyaK1MXhvFejtQ%3D%3D (Pubitemid 29018747)
8. FS Leach T Tokino P Meltzer, et al. 1993 p53 Mutation and MDM2 amplification in human soft tissue sarcomas Cancer Res 53 2231 2234 8387391 1:STN:280:DyaK3s3ltFCnsQ%3D%3D (Pubitemid 23156805)
9. JD Oliner KW Kinzler PS Meltzer DL George B Vogelstein 1992 Amplification of a gene encoding a p53-associated protein in human sarcomas Nature 358 80 83 1614537 10.1038/358080a0 1:CAS:528:DyaK3sXisFagsbs%3D
10. J Momand D Jung S Wilczynski J Niland 1998 The MDM2 gene amplification database Nucleic Acids Res 26 3453 3459 9671804 10.1093/nar/26.15.3453 1:CAS:528:DyaK1cXltlKqsr4%3D (Pubitemid 28347214)
11. GL Bond KM Hirshfield T Kirchhoff, et al. 2006 MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner Cancer Res 66 5104 5110 16707433 10.1158/0008-5472.CAN-06-0180 1:CAS:528:DC%2BD28XksF2isr0%3D (Pubitemid 43844932)
12. DG Cox D Deer Q Guo, et al. 2007 The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies Cancer Causes Control 18 621 625 17387621 10.1007/s10552-007-9004-x (Pubitemid 46883679)
13. OM Sinilnikova AC Antoniou J Simard, et al. 2009 The TP53 Arg72Pro and MDM2 309G >T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers Br J Cancer 101 1456 1460 19707196 10.1038/sj.bjc.6605279 1:CAS:528:DC%2BD1MXht1Gnur%2FN
14. MK Schmidt S Reincke A Broeks, et al. 2007 Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium Cancer Res 67 9584 9590 17909070 10.1158/0008-5472.CAN-07-0738 1:CAS:528:DC%2BD2sXhtFSnurjL (Pubitemid 47535950)
15. M Li Z Zhang DL Hill X Chen H Wang R Zhang 2005 Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels Cancer Res 65 8200 8208 16166295 10.1158/0008-5472.CAN- 05-1302 1:CAS:528:DC%2BD2MXhtVShsbvL (Pubitemid 41330583)
16. H Wang L Nan D Yu S Agrawal R Zhang 2001 Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms Clin Cancer Res 7 3613 3624 11705884 1:CAS:528:DC%2BD3MXptFaisb8%3D (Pubitemid 33070002)
17. AH Wu WP Koh R Wang HP Lee MC Yu 2008 Soy intake and breast cancer risk in Singapore Chinese Health Study Br J Cancer 99 196 200 18594543 10.1038/sj.bjc.6604448 1:CAS:528:DC%2BD1cXnvFeqs7s%3D (Pubitemid 351920241)
18. JH Hankin DO Stram K Arakawa, et al. 2001 Singapore Chinese Health Study: development, validation, and calibration of the quantitative food frequency questionnaire Nutr Cancer 39 187 195 11759279 10.1207/S15327914nc392-5 1:CAS:528:DC%2BD3MXpt1Wht7w%3D (Pubitemid 33694034)
19. AA Franke JH Hankin MC Yu G Maskarinec SH Low LJ Custer 1999 Isoflavone levels in soy foods consumed by multiethnic populations in Singapore and Hawaii J Agric Food Chem 47 977 986 10552401 10.1021/jf9808832 1:CAS:528: DyaK1MXntlaitQ%3D%3D (Pubitemid 29182948)
20. CL Sun JM Yuan K Arakawa SH Low HP Lee MC Yu 2002 Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study Cancer Epidemiol Biomarkers Prev 11 1674 1677 12496060 (Pubitemid 36020023)
21. A Seow CY Shi AA Franke JH Hankin HP Lee MC Yu 1998 Isoflavonoid levels in spot urine are associated with frequency of dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore Cancer Epidemiol Biomarkers Prev 7 135 140 9488588 1:CAS:528:DyaK1cXhtlSms7w%3D (Pubitemid 28109845)
22. WP Koh JM Yuan CL Sun, et al. 2003 Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore Cancer Res 63 573 578 12566298 1:CAS:528:DC%2BD3sXosVyjsA%3D%3D
23. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas D (2002) Cancer incidence in five continents. IARC, Lyon
24. LG Lee CR Connell W Bloch 1993 Allelic discrimination by nick-translation PCR with fluorogenic probes Nucleic Acids Res 21 3761 3766 8367293 10.1093/nar/21.16.3761 1:CAS:528:DyaK3sXmtFymsrs%3D (Pubitemid 23254498)
25. Breslow NE, Day NE (1980) Statistical methods in cancer research. In: The analysis of case-control studies, Vol 1. IARC, Lyon
26. JM Yuan WP Koh CL Sun HP Lee MC Yu 2005 Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore Carcinogenesis 26 1389 1394 15802301 10.1093/carcin/bgi080 1:CAS:528: DC%2BD2MXmsV2isLo%3D (Pubitemid 41430093)
27. D Pim L Banks 2004 p53 polymorphic variants at codon 72 exert different effects on cell cycle progression Int J Cancer 108 196 199 14639602 10.1002/ijc.11548 1:CAS:528:DC%2BD3sXhtVWgu7zI (Pubitemid 37541770)
28. E Biros I Kalina I Biros, et al. 2001 Polymorphism of the p53 gene within the codon 72 in lung cancer patients Neoplasma 48 407 411 11845987 1:CAS:528:DC%2BD38Xislelug%3D%3D (Pubitemid 33144720)
29. M Bonafe F Olivieri D Mari, et al. 1999 P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia Am J Hum Genet 65 1782 1785 10577935 10.1086/302664 1:CAS:528: DC%2BD3cXjvFelug%3D%3D (Pubitemid 30468693)
30. N Soulitzis G Sourvinos DN Dokianakis DA Spandidos 2002 p53 codon 72 polymorphism and its association with bladder cancer Cancer Lett 179 175 183 11888672 10.1016/S0304-3835(01)00867-9 1:CAS:528:DC%2BD38XhvVWmurg%3D (Pubitemid 34215109)
31. A Storey M Thomas A Kalita, et al. 1998 Role of a p53 polymorphism in the development of human papillomavirus-associated cancer Nature 393 229 234 9607760 10.1038/30400 1:CAS:528:DyaK1cXjtlymtLs%3D (Pubitemid 28261713)
32. Y Sun C Keshava DS Sharp A Weston EC McCanlies 1999 DNA sequence variants of p53: cancer and aging Am J Hum Genet 65 1779 1782 10577934 10.1086/302650 1:CAS:528:DC%2BD3cXjvFeltQ%3D%3D (Pubitemid 30468692)
33. X Wu H Zhao CI Amos, et al. 2002 p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity J Natl Cancer Inst 94 681 690 11983757 10.1093/jnci/94.9.681 1:CAS:528:DC%2BD38XktFWlsL4%3D (Pubitemid 34552489)
34. H Shen A Solari X Wang, et al. 2004 P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population Oncol Rep 11 1115 1120 15069555 1:CAS:528:DC%2BD2cXjslGksLo%3D
35. MW Yu SY Yang YH Chiu YC Chiang YF Liaw CJ Chen 1999 A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers Hepatology 29 697 702 10051470 10.1002/hep.510290330 1:CAS:528:DyaK1MXhvFyjsrk%3D
36. YC Wang CY Chen SK Chen YY Chang P Lin 1999 p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis Clin Cancer Res 5 129 134 9918210 1:CAS:528:DyaK1MXhtVShtLc%3D (Pubitemid 29045185)
37. A Sjalander R Birgander G Hallmans, et al. 1996 p53 polymorphisms and haplotypes in breast cancer Carcinogenesis 17 1313 1316 8681448 10.1093/carcin/17.6.1313 1:STN:280:DyaK283otFKqsw%3D%3D (Pubitemid 26196343)
38. Y Ma J Yang Z Liu, et al. 2011 No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24, 063 subjects Breast Cancer Res Treat 125 201 205 20496166 10.1007/s10549-010-0920-1
39. W Zhuo Y Zhang Z Xiang L Cai Z Chen 2009 Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls J Exp Clin Cancer Res 28 115 19682377 10.1186/1756-9966-28-115
40. MM Siddique C Balram L Fiszer-Maliszewska, et al. 2005 Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development Cancer Epidemiol Biomarkers Prev 14 2245 2252 16172238 10.1158/1055-9965.EPI-05-0153 1:CAS:528:DC%2BD2MXhtVWgtbvN (Pubitemid 41603274)
41. S Wilkening JL Bermejo K Hemminki 2007 MDM2 SNP309 and cancer risk: a combined analysis Carcinogenesis 28 2262 2267 17827408 10.1093/carcin/bgm191 1:CAS:528:DC%2BD2sXht1yktbbI (Pubitemid 350119563)
42. KP Economopoulos TN Sergentanis 2009 Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis Breast Cancer Res Treat 120 211 216 19590949 10.1007/s10549-009-0467-1
43. BJ Boersma TM Howe JE Goodman, et al. 2006 Association of breast cancer outcome with status of p53 and MDM2 SNP309 J Natl Cancer Inst 98 911 919 16818855 10.1093/jnci/djj245 1:CAS:528:DC%2BD28Xms1OhtL4%3D (Pubitemid 44018921)
44. AH Wu MC Yu CC Tseng MC Pike 2008 Epidemiology of soy exposures and breast cancer risk Br J Cancer 98 9 14 18182974 10.1038/sj.bjc.6604145 1:CAS:528:DC%2BD1cXisF2rsQ%3D%3D
45. GG Kuiper JG Lemmen B Carlsson, et al. 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta Endocrinology 139 4252 4263 9751507 10.1210/en.139.10.4252 1:CAS:528:DyaK1cXmsVGmsrw%3D (Pubitemid 28513713)
46. D Kostelac G Rechkemmer K Briviba 2003 Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element J Agric Food Chem 51 7632 7635 14664520 10.1021/jf034427b 1:CAS:528: DC%2BD3sXovVOhtL4%3D
47. S Paruthiyil H Parmar V Kerekatte GR Cunha GL Firestone DC Leitman 2004 Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest Cancer Res 64 423 428 14729654 10.1158/0008-5472.CAN-03-2446 1:CAS:528:DC%2BD2cXkslyqtw%3D%3D (Pubitemid 38114127)
48. A Strom J Hartman JS Foster S Kietz J Wimalasena JA Gustafsson 2004 Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D Proc Natl Acad Sci USA 101 1566 1571 14745018 10.1073/pnas.0308319100 (Pubitemid 38236167)
49. EC Chang J Frasor B Komm BS Katzenellenbogen 2006 Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells Endocrinology 147 4831 4842 16809442 10.1210/en.2006-0563 1:CAS:528:DC%2BD28XhtVSksbvK (Pubitemid 44402189)
50. T Akiyama J Ishida S Nakagawa, et al. 1987 Genistein, a specific inhibitor of tyrosine-specific protein kinases J Biol Chem 262 5592 5595 3106339 1:CAS:528:DyaL2sXktF2rurk%3D
51. X Kang S Jin Q Zhang 2009 Antitumor and antiangiogenic activity of soy phytoestrogen on 7, 12-dimethylbenz[alpha]anthracene-induced mammary tumors following ovariectomy in Sprague-Dawley rats J Food Sci 74 H237 H242 19895476 10.1111/j.1750-3841.2009.01278.x 1:CAS:528:DC%2BD1MXht1ajtb3E